With the AI competition intensifying, we see tech rivalry going beyond strategy differences to personal attacks, and this week was not pretty in terms of the spat between OpenAI's CEO, Sam Altman, and X's CEO, Elon Musk. The conflict has garnered quite a bit of attention, but that is not the only thing that Altman is focused on as he aims to take another major step by pivoting in the direction of a brain–computer interface in a new startup called Merge Labs. This would make the AI company a direct rival to Musk's Neuralink.
Sam Altman's new startup, Merge Labs, is aimed at fusing human minds and machines in a bold challenge to Neuralink
OpenAI CEO Sam Altman is not slowing down when it comes to establishing himself as a tech leader and is now entering the brain–computer interface (BCI) race with his new venture, Merge Labs, as per a Financial Times report. This would set it up as a direct competitor to Elon Musk's Neuralink and further intensify the ongoing rivalry. The company is actively being co-founded with Alex Blania, who is the main mind behind the iris-scanning digital ID project Worldcoin. Currently, the company is being established, and multiple reports suggest that the startup is already valued at approximately $850 million, aiming to raise another $250 million, with a major chunk coming from OpenAI's venture arm.
While Altman helped found the company, the report suggests that he would not be personally invested in the day-to-day operations of Merge Labs and is more interested in going ahead with his ambitious goal of blending human cognition with artificial intelligence. Altman predicted the merger back in 2017 and even went on to suggest that it would happen sometime by 2025. The startup intends to work on high-bandwidth BCIs, but unlike Neuralink, it would focus on more widely scalable and less invasive methods. It intends to have broader uses than merely medical applications and develop brain–machine links that are more responsive and quicker.
Neuralink, on the other hand, has the upper hand because the company is already conducting human trials and has a hefty $9 billion valuation. It was also able to raise around $650 million this year alone and achieved a major milestone with a patient with a brain implant controlling a cursor with their thoughts back in 2024. The clash between the two parties has gone beyond AI, which adds another layer of intrigue for the community, as the BCI development race could accelerate things further.
Merge Labs should take a cautious approach, given that such innovations tend to raise ethical concerns, and the success of human–machine integration is not limited to the technical breakthrough alone.
Follow Wccftech on Google to get more of our news coverage in your feeds.
